Clinical Planning Manager Job in Cambridge 02139, Massachusetts Us
The Clinical Planning Manager will serves as the “point person” to provide valuable analysis and clinical forecasts concerning the business needs within Clinical Development. Specific areas of expertise will include a strong business perspective, strategic planning, ability to develop and manage timelines, and present findings to related business partners. This position will work closely with and report directly to the Chief Medical Officer.
Responsibilities include but are not limited to the following:
- Provide financial analysis, forecasting, cost analysis, and long-range planning.
- Prepare and present findings to cross functional teams.
- Serve as a liaison between clinical and other departments such as business development and finance.
- Understand and quantify the financial impact of the utilization of external vendors in comparison to internal resources.
- Develop and manage timelines as in relates to clinical financial functions.
- Prepare and maintain internal reports utilizing Excel, PowerPoint and other relevant applications.
- Identify and streamline areas for process improvement.
Qualifications
- MBA with BS/BA in life sciences is preferred.
- 1+ yrs of industry experience or internship (biotech/pharma/ CRO).
- Excellent verbal and written communication skills.
- Excellent interpersonal skills and ability to interact effectively and productively.
- Excellent organizational skills and attention to detail.
- Proficiency with Microsoft Outlook, Excel, Word, PowerPoint and Project.
We welcome your expertise, your insight and your enthusiasm to help us develop and commercialize novel drugs that bring new hope to cancer patients.
About AVEO
AVEO Pharmaceuticals (NASDAQ: AVEO) integrates a proprietary cancer biology platform with drug development and commercial expertise in its efforts to discover and develop targeted cancer therapeutics. The company's lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with a highly differentiated profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEO's proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development and has provided a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch, and FGFR. For more information, please visit the company's website at www.aveopharma.com .